Europe Virus-like Particles Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Hepatitis, Cancer/HPV, and Gaucher disease), Source (Yeast, Insect Cell, Plant, and Others), and Application (Vaccines and Therapeutics)
Market Introduction
Europe comprises five prominent countries, namely Germany, France, UK, Italy, and Spain. The market also comprises the rest of the countries in Europe. Europe's virus-like particles market is witnessing stronger growth due to new product approvals by the authorized bodies. For example, the first licensed malaria VLP based vaccine namely, "Mosquirix," was approved by the European regulators. In addition, countries like the UK, Germany, France, Italy, and Spain are the key contributing countries driving the demand for virus-like particles products in Europe.
As per the World Health Organization (WHO) report, currently, every single country in Europe is facing a real threat of COVID-19. The pace of virus transmission across the 53 countries of the WHO European Region is a matter of concern. To control the transmission, countries of Europe are conducting vaccination roll-outs at various stages. In Europe, various COVID-19 vaccines are currently being developed and are in clinical trials, in the countries such as the UK, Germany, and Russia. Among them, there are three vaccines in the UK, three vaccines in Germany, and 2 in Russia. Among these vaccines, there is one inactivated vaccine, two protein subunits, three viral vector vaccines, and two nucleic acid vaccines. To combat the coronavirus in the European region, Europe as a whole has made consistent efforts to drive vaccine development. The Bruegel report states that, prior to the COVID-19 pandemic, the EU announced funding of almost US$500 Million for vaccine and vaccination research through the Horizon 2020 research program during 2014-2020. Additionally, to combat COVID-19, the EU has offered emergency funds to support research and development for diagnostics, therapeutics, and vaccines. Initially, US$10 Million subsequently increased to US$ 47.5 Million and was allotted for research projects for responding to the COVID-19 pandemic. Moreover, the European Institute of Technology Health opened in April 2020 was a call to EIT partners to send proposals for COVID-19 projects with robust implementation with funding of each project.
Get more information on this report :
Market Overview and Dynamics
The virus-like particles market in Europe is expected to grow from US$ 1,302.03 million in 2021 to US$ 2,203.61 million by 2028; it is estimated to grow at a CAGR of 7.8% from 2021 to 2028. Vaccines form one of the significant segments of the pharmaceuticals industry. They have an extensive application in the immunization of humans and animals against common infections. Companies operating in the pharmaceuticals and biopharmaceuticals markets continuously focus on product innovations and developments to sustain competition in the market. For instance, the market players have been significantly investing in the development of vaccines against COVID-19 and studies related to VLP. The active developments by life sciences companies, coupled with government support for the same, is contributing to the VLP market growth.
Key Market Segments
In terms of product type, the hepatitis segment accounted for the largest share of the Europe virus-like particles market in 2021. In terms of source, the yeast segment accounted for the largest share of the Europe virus-like particles market in 2021. In term of application, vaccines segment held a larger market share of the virus-like particles market in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the virus-like particles market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Merck & Co., Inc.; GlaxoSmithKline plc.; Pfizer Inc.; Sanofi; Serum Institute of India Pvt. Ltd.; BHARAT BIOTECH; LG Chem; and Dynavax Technologies among others.
Reasons to buy report
- To understand the Europe virus-like particles market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe virus-like particles market
- Efficiently plan M&A and partnership deals in Europe virus-like particles market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe virus-like particles market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
Europe Virus-like Particles Market Segmentation
Europe Virus-like Particles Market – By Product type
- Hepatitis
- Cancer/HPV
- Gaucher Disease
Europe Virus-like Particles Market – By Source
- Yeast
- Insect Cell
- Plant
- Others
Europe Virus-like Particles Market – By Application
- Vaccines
- Therapeutics
Europe Virus-like Particles Market – By Country
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Europe Virus-like Particles Market – Companies Mentioned
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- Dynavax Technologies
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Virus-like Particles Market – By Product Type
1.3.2 Europe Virus-like Particles Market – By Source
1.3.3 Europe Virus-like Particles Market – By Application
1.3.4 Europe Virus-like Particles Market – By Country
2. Europe Virus-like Particles Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Virus-like Particles Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. Europe Virus-like Particles Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Raising Prevalence of Infectious Viral Diseases
5.1.2 The Growing Role of Virus-Like Particles in Therapeutic Developments and Studies
5.2 Market Restraints
5.2.1 Access of Alternative Technologies for Viral Vaccine Production
5.3 Market Opportunities
5.3.1 Boosting Potential Applications in Therapeutics and Diagnostics
5.4 Future Trends
5.4.1 Ongoing Demand for Innovative and Effective Products
5.5 Impact Analysis
6. Europe Virus-like Particles Market Analysis
6.1 Europe Virus-like Particles Market Revenue Forecast and Analysis
7. Europe Virus-like Particles Market Analysis – by Product Type
7.1 Overview
7.2 Europe Virus-like Particles Market, by Product Type, 2021 & 2028 (%)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
7.4 Cancer/ Human Papillomavirus (HPV)
7.4.1 Overview
7.4.2 Cancer/HPV: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
7.5 Gaucher Disease
7.5.1 Overview
7.5.2 Gaucher Disease: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8. Europe Virus-like Particles Market Analysis – By Source
8.1 Overview
8.2 Europe Virus-like Particles Market Share, by Source, 2021 & 2028 (%)
8.3 Yeast
8.3.1 Overview
8.3.2 Yeast: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.4 Plant
8.4.1 Overview
8.4.2 Plant: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.5 Insect Cell
8.5.1 Overview
8.5.2 Insect Cell: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
9. Europe Virus-like Particles Market Analysis – By Application
9.1 Overview
9.2 Europe Virus-like Particles Market Share, by Application, 2021 & 2028 (%)
9.3 Vaccines
9.3.1 Overview
9.3.2 Vaccine: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
9.4 Therapeutics
9.4.1 Overview
9.4.2 Therapeutics: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10. Europe Virus-like Particles Market – Country Analysis
10.1 Overview
10.1.1 Europe: Virus-like Particles Market, by Country, 2021 & 2028(%)
10.1.1.1 Germany: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 Germany: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.4 Germany: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.5 Germany Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.2 France: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 France: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 France: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.4 France: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.5 France Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.3 UK: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 UK: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 UK: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.4 UK: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.5 UK Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.4 Italy: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.3 Italy: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.4 Italy: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.5 Italy Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.5 Spain: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.3 Spain: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.4 Spain: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.5 Spain Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.6 Rest of Europe: Virus-Like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.3 Rest of Europe: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.4 Rest of Europe: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.5 Rest of Europe Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
11. Impact Of COVID-19 Pandemic on Europe Virus-like Particles Market
11.1 Impact Assessment of COVID-19 Pandemic
12. Europe Virus-like Particles Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Dynavax Technologies
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sanofi
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Serum Institute of India Pvt. Ltd.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 BHARAT BIOTECH
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 LG Chem
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Virus-like Particles Market, Revenue and Forecast to 2028 (US$ Million)
Table 2. Germany: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 4. Germany Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 5. France: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. France: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 7. France Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 8. UK: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. UK: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 10. UK Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 11. Italy: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Italy: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 13. Italy Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 14. Spain: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. Spain: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 16. Spain Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Europe: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Europe: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of Europe Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 20. Organic Developments Done by Companies
Table 21. Inorganic Developments Done by Companies
Table 22. Glossary of Terms: Virus-like Particles Market
LIST OF FIGURES
Figure 1. Europe Virus-like particles Market Segmentation
Figure 2. Europe Virus-like particles Market Segmentation, By Country
Figure 3. Europe Virus-like Particles Market Overview
Figure 4. Hepatitis Held the Largest Share of the Product Type Segment in Europe Virus-like particles Market
Figure 5. The UK to Show Significant Growth during Forecast Period
Figure 6. Europe Virus-like Particles Market, Industry Landscape
Figure 7. Europe PEST Analysis
Figure 8. Europe Virus-like Particles Market: Impact Analysis of Drivers and Restraints
Figure 9. Europe Virus-like Particles Market– Revenue Forecast and Analysis to 2028
Figure 10. Europe Virus-like Particles Market, by Product Type, 2021 & 2028 (%)
Figure 11. Hepatitis: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 12. Cancer/HPV: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 13. Gaucher Disease: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 14. Europe Virus-like Particles Market Share, by Source, 2021 & 2028 (%)
Figure 15. Yeast: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Plant: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Insect Cell: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Others: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Europe Virus-like Particles Market Share, by Application, 2021 & 2028 (%)
Figure 20. Vaccine: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Therapeutics: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Europe: Virus-like Particles Market, by Key Country – Revenue (2021) (USD Million)
Figure 23. Europe: Virus-like Particles Market, by Country, 2021 & 2028 (%)
Figure 24. Germany: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. France: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. UK: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Italy: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Spain: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Rest of Europe: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Impact of COVID-19 Pandemic in European Country Markets
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- Dynavax Technologies
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe virus-like particles market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe virus-like particles market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the virus-like particles market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution